Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
2.

Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):77-83. doi: 10.1038/s41391-018-0090-5. Epub 2018 Sep 13.

PMID:
30214036
3.

The association between sexual function and prostate cancer risk in US veterans.

Zapata DF, Howard LE, Frank J, Simon RM, Hoyo C, Grant DJ, Freedland SJ, Vidal AC.

Asian J Androl. 2017 Mar-Apr;19(2):191-195. doi: 10.4103/1008-682X.184869.

4.

Metformin use and risk of prostate cancer: results from the REDUCE study.

Feng T, Sun X, Howard LE, Vidal AC, Gaines AR, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.

Cancer Prev Res (Phila). 2015 Nov;8(11):1055-60. doi: 10.1158/1940-6207.CAPR-15-0141. Epub 2015 Sep 9.

5.

Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.

Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.

Clin Cancer Res. 2015 Feb 15;21(4):756-62. doi: 10.1158/1078-0432.CCR-14-2235. Epub 2014 Dec 17.

6.

Lifestyle and lower urinary tract symptoms: what is the correlation in men?

Lin PH, Freedland SJ.

Curr Opin Urol. 2015 Jan;25(1):1-5. doi: 10.1097/MOU.0000000000000121. Review.

7.

Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, Vidal AC.

BJU Int. 2015 May;115(5):736-43. doi: 10.1111/bju.12843. Epub 2014 Oct 20.

8.

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.

Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7. doi: 10.1038/pcan.2013.48. Epub 2013 Oct 8.

9.

Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2014 Apr;65(4):816-24. doi: 10.1016/j.eururo.2013.02.023. Epub 2013 Feb 22.

10.

Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database.

Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2013 Jun;111(8):E310-8. doi: 10.1111/j.1464-410X.2012.11687.x. Epub 2013 Jan 10.

11.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley A, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. No abstract available.

12.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2013 Jul;64(1):159-66. doi: 10.1016/j.eururo.2012.04.035. Epub 2012 Apr 19.

13.

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81. doi: 10.1158/1055-9965.EPI-11-1017. Epub 2012 Feb 7.

14.

Diabetes and prostate cancer risk in the REDUCE trial.

Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):326-31. doi: 10.1038/pcan.2011.28. Epub 2011 Jun 28.

PMID:
21709690
15.

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.

Moreira DM, Anderson T, Gerber L, Thomas JA, Bañez LL, McKeever MG, Hoyo C, Grant D, Jayachandran J, Freedland SJ.

Cancer Causes Control. 2011 Jul;22(7):977-83. doi: 10.1007/s10552-011-9770-3. Epub 2011 May 12.

PMID:
21562753
16.

Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

Saylor PJ, Keating NL, Freedland SJ, Smith MR.

Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000. No abstract available.

17.

Glycemic control and prostate cancer progression: results from the SEARCH database.

Kim HS, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.

Prostate. 2010 Oct 1;70(14):1540-6. doi: 10.1002/pros.21189.

18.

Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database.

Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):9-17. doi: 10.1158/1055-9965.EPI-09-0777.

19.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

20.

Examining the relationship between obesity and prostate cancer.

Freedland SJ, Aronson WJ.

Rev Urol. 2004 Spring;6(2):73-81.

Supplemental Content

Loading ...
Support Center